|
May 19
|
GSK’s Blood-Cancer Treatment Combinations Approved in Japan
|
|
Apr 17
|
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
|
|
Apr 17
|
UK Becomes First Country To Authorize Blenrep In Two Combo Regimens
|
|
Apr 17
|
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
|
|
Apr 16
|
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
|
|
Apr 16
|
GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
|
|
Feb 17
|
GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q3 2025 Earnings Call Highlights: Strong ...
|
|
Feb 15
|
GSK shares shorted by leading U.S. hedge fund, The Times reports
|
|
Feb 15
|
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
|
|
Feb 14
|
Hedge fund Citadel takes short position in GSK, FT reports
|
|
Feb 13
|
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
|
|
Feb 12
|
Some May Be Optimistic About GSK's (LON:GSK) Earnings
|
|
Feb 11
|
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
|
|
Feb 10
|
Recent uptick might appease GSK plc (LON:GSK) institutional owners after losing 7.8% over the past year
|
|
Jan 29
|
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
|
|
Jan 29
|
GSK announces EMA accepted for review the MAA for depemokimab
|
|
Jan 29
|
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
|
|
Jan 27
|
GSK and Oxford researchers to create cancer vaccine to stop disease developing
|
|
Jan 27
|
Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK
|